ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
European Medicines Agency Accepts Marketing Authorisation Application for Prestige BioPharma’s Trastuzumab Biosimilar HD201 for Review
May 29, 2019European Medicines Agency Accepts Marketing Authorisation Application for Prestige BioPharma’s Trastuzumab Biosimilar HD201 for Review. -
EMA accepts Prestige Biopharma's MAA for review
May 29, 2019HD201 is Prestige’s first biosimilar to receive a positive Committee for Medicinal Products for Human Use (CHMP) opinion for marketing authorization from the EMA. -
Prestige, Cipla unite to sell cancer biosimilar HD201
December 17, 2018HD201 is a mAb biosimilar to Roche’s Herceptin® which is used to treat patients with HER2-overexpressing breast cancer, HER2-overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma.
Pharma Sources Insight January 2025
